DiscoverDiabetes Dialogue: Technology, Therapeutics, & Real-World PerspectivesBELIEVE, GLP-1/GIP Agonists, and CATALYST Results at ADA 2025
BELIEVE, GLP-1/GIP Agonists, and CATALYST Results at ADA 2025

BELIEVE, GLP-1/GIP Agonists, and CATALYST Results at ADA 2025

Update: 2025-07-16
Share

Description

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, continue their recap of ADA’s 2025 Scientific Sessions, spotlighting 3 more of the top clinical trials focused on obesity and type 2 diabetes.



00:00:00 Intro



00:00:31 BELIEVE Trial



00:08:11 Phase 2 Maritide Trial



00:17:12 CATALYST-2
Comments 
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

BELIEVE, GLP-1/GIP Agonists, and CATALYST Results at ADA 2025

BELIEVE, GLP-1/GIP Agonists, and CATALYST Results at ADA 2025

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives